Biblio
2018
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am J Hematol. 2018.
2020
Le Gouill S, Beldi-Ferchiou A, Alcantara M, Cacheux V, Safar V, Burroni B, Guidez S, Gastinne T, Canioni D, Thieblemont C, et al. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematol. 2020.
2022
Younan N, Soussain C, Choquet S, Cassoux N, Touitou V, Schmitt A, Chinot O, Obéric L, Damaj G, Houot R, et al. Isolated intraocular relapses of primary cerebral lymphomas: AN LOC NETWORK STUDY. Hematol Oncol. 2022.
]